Lipidor, Cadila Sign Agreement for Phase III Trial of AKP-02

Lipidor AB entered an agreement with Cadila Pharmaceuticals to conduct a Phase III study for Lipidor's drug candidate AKP-02. The study is expected to begin 1Q21 with final reporting in 1Q22.

AKP-02 is an antipsoriasis medicine that combines the active substances calcipotriol and betamethasone with Lipidor's spray-based AKVANO technology. An agreement has now been concluded with Cadila Pharmaceuticals for the implementation of the study.

The Phase III study is expected to enroll 270 patients and will be conducted in India on patients with various skin types. The intention is to demonstrate equivalent therapeutic efficacy with existing medicines for mild to moderate psoriasis. The observer-blind and placebo-controlled trial is expected to be completed in 4Q21.  

Lipidor is funding the Phase III study. Discussions with clinical trial material manufacturers are ongoing and an agreement is expected to be in place in 3Q20.